Literature DB >> 10732765

Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells.

A Di Paolo1, R Danesi, D Nardini, G Bocci, F Innocenti, S Fogli, S Barachini, A Marchetti, G Bevilacqua, M Del Tacca.   

Abstract

The aim of the present study was to assess the cytotoxicity of manumycin, a specific inhibitor of farnesyl:protein transferase, as well as its effects on protein isoprenylation and kinase-dependent signal transduction in COLO320-DM human colon adenocarcinoma which harbours a wild-type K-ras gene. Immunoblot analysis of isolated cell membranes and total cellular lysates of COLO320-DM cells demonstrated that manumycin dose-dependently reduced p21 ras farnesylation with a 50% inhibitory concentration (IC50) of 2.51 +/- 0.11 microM and 2.68 +/- 0.20 microM, respectively, while the geranylgeranylation of p21 rhoA and p21rap1 was not affected. Manumycin dose-dependently inhibited (IC50 = 2.40 +/- 0.67 microM) the phosphorylation of the mitogen-activated protein kinase/extracellular-regulated kinase 2 (p42MAPK/ERK2), the main cytoplasmic effector of p21ras, as well as COLO320-DM cell growth (IC50 = 3.58 +/- 0.27 microM) without affecting the biosynthesis of cholesterol. Mevalonic acid (MVA, 100 microM), a substrate of the isoprenoid synthesis, was unable to protect COLO320-DM cells from manumycin cytotoxicity. Finally, manumycin 1-25 microM for 24-72 h induced oligonucleosomal fragmentation in a dose- and time-dependent manner and MVA did not protect COLO320-DM cells from undergoing DNA cleavage. The present findings indicate that the inhibition of p21ras processing and signal transduction by manumycin is associated with marked inhibition of cell proliferation and apoptosis in colon cancer cells and the effect on cell growth does not require the presence of a mutated ras gene for maximal expression of chemotherapeutic activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10732765      PMCID: PMC2374379          DOI: 10.1054/bjoc.1999.1018

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  30 in total

Review 1.  The potential of farnesyltransferase inhibitors as cancer chemotherapeutics.

Authors:  J B Gibbs; A Oliff
Journal:  Annu Rev Pharmacol Toxicol       Date:  1997       Impact factor: 13.820

Review 2.  Ras effectors.

Authors:  C J Marshall
Journal:  Curr Opin Cell Biol       Date:  1996-04       Impact factor: 8.382

Review 3.  Targeting signal transduction for disease therapy.

Authors:  A Levitzki
Journal:  Curr Opin Cell Biol       Date:  1996-04       Impact factor: 8.382

Review 4.  Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?

Authors:  A D Cox; C J Der
Journal:  Biochim Biophys Acta       Date:  1997-08-08

5.  Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels.

Authors:  F Larcher; A I Robles; H Duran; R Murillas; M Quintanilla; A Cano; C J Conti; J L Jorcano
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

6.  Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells.

Authors:  J H Veerkamp; J W Smit; A A Benders; A Oosterhof
Journal:  Biochim Biophys Acta       Date:  1996-04-12

Review 7.  Posttranslational modification of proteins by isoprenoids in mammalian cells.

Authors:  W A Maltese
Journal:  FASEB J       Date:  1990-12       Impact factor: 5.191

8.  Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.

Authors:  S Rodenhuis; L Boerrigter; B Top; R J Slebos; W J Mooi; L van't Veer; N van Zandwijk
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

Review 9.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

10.  Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene.

Authors:  R Danesi; D Nardini; F Basolo; M Del Tacca; D Samid; C E Myers
Journal:  Mol Pharmacol       Date:  1996-06       Impact factor: 4.436

View more
  8 in total

1.  Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.

Authors:  Toshiyuki Kusama; Mutsuko Mukai; Masaharu Tatsuta; Yoshirou Matsumoto; Hiroyuki Nakamura; Masahiro Inoue
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

2.  Enhanced antiproliferative and apoptotic response of HT-29 adenocarcinoma cells to combination of photoactivated hypericin and farnesyltransferase inhibitor manumycin A.

Authors:  Veronika Sačková; Lucia Kuliková; Martin Kello; Ivana Uhrinová; Peter Fedoročko
Journal:  Int J Mol Sci       Date:  2011-11-29       Impact factor: 5.923

3.  Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells.

Authors:  A Di Paolo; R Danesi; S Caputo; M Macchia; M Lastella; U Boggi; F Mosca; A Marchetti; M Del Tacca
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

4.  Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells.

Authors:  G Bocci; A Fioravanti; P Orlandi; N Bernardini; P Collecchi; M Del Tacca; R Danesi
Journal:  Br J Cancer       Date:  2005-08-08       Impact factor: 7.640

5.  Inhibition of Pro-Inflammatory Cytokines by Metabolites of Streptomycetes-A Potential Alternative to Current Anti-Inflammatory Drugs?

Authors:  Jiří Hrdý; Lenka Súkeníková; Petra Petrásková; Olga Novotná; David Kahoun; Miroslav Petříček; Alica Chroňáková; Kateřina Petříčková
Journal:  Microorganisms       Date:  2020-04-25

Review 6.  Natural Products from Actinobacteria as a Potential Source of New Therapies Against Colorectal Cancer: A Review.

Authors:  Yadollah Bahrami; Sasan Bouk; Elham Kakaei; Mohammad Taheri
Journal:  Front Pharmacol       Date:  2022-07-11       Impact factor: 5.988

7.  Manumycin A inhibits triple-negative breast cancer growth through LC3-mediated cytoplasmic vacuolation death.

Authors:  P K Singha; S Pandeswara; M A Venkatachalam; P Saikumar
Journal:  Cell Death Dis       Date:  2013-01-17       Impact factor: 8.469

Review 8.  Ras and autophagy in cancer development and therapy.

Authors:  Eran Schmukler; Yoel Kloog; Ronit Pinkas-Kramarski
Journal:  Oncotarget       Date:  2014-02-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.